BI 3000202の異なる用量が全身性エリテマトーデス（SLE）患者に効果があるかどうかを検証する研究

基本情報

NCT ID

NCT07409181

ステータス

募集前

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

405

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

対象疾患

介入

依頼者（Sponsor）

実施施設 (15)